Mabs directed against the cell surface antigens, CD19 and CD22 conjugated to deglycosylated ricin A chain (dgRTA) have been tested in patients with non-Hodgkin's lymphoma (NHL), but not in ...

The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma ...

Celularity Inc.’s CELU share price has dipped by 11.11%, which has investors questioning if this is right time to buy.

High school basketball: Scores for boys’ and girls’ games across the Southland on Friday, Feb. 7. High school basketball: Scores for boys’ and girls’ games across the Southland on Thursday ...

Personalized medicine advances as autologous cell therapy grows, leveraging refined cell collection, improved processing ...

Feb. 4, 2025 — Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in preclinical models tested in mice.

Commissions do not affect our editors' opinions or evaluations. High-yield checking accounts offer debit cards, check-writing privileges and above-average interest rates. The best high-yield ...

Commissions do not affect our editors' opinions or evaluations. The best high-yield savings account is Capital One 360 Performance Savings Account™, earning the top rating of 5.0 stars in our study.

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical giant with a market capitalization of $120.8 billion, finds ...

Single-cell multi-omic technologies, including flow cytometry, single-cell transcriptomics, and single-cell T-cell receptor (TCR) and B-cell receptor (BCR) profiling, offer a better solution to ...